United States

Analyst Research Report Snapshot


ImmunoGen, Inc






06 Jul 2015





Companies referenced:


Available for Immediate Download

ImmunoGen, Inc - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360° view of the company. Features: - Detailed information on ImmunoGen, Inc required for business and competitor intelligence needs - A study of the major internal and external factors affecting ImmunoGen, Inc in the form of a SWOT analysis - An in-depth view of the business model of ImmunoGen, Inc including a breakdown and examination of key business segments - Intelligence on ImmunoGen, Inc’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about ImmunoGen, Inc, such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: ImmunoGen (or ‘the company’) is a developer of targeted anticancer therapeutics using its antibody-drug conjugate (ADC) technology. The ADC technology comprises the company’s portfolio of cancer-cell killing agents that can be attached to antibodies for targeted delivery to cancer cells. ImmunoGen is headquartered in Waltham, Massachusetts, and employed 280 people as of June 30, 2013. The company recorded revenues of $35.5 million during the financial year ended June 2013 (FY2013), as compared to the revenues of $16.4 million in FY2012. The operating loss of the company was $73 million in FY2013, as compared to an operating loss of $73.3 million in FY2012. The net loss was $72.8 million in FY2013, as compared to a net loss of $73.3 million in FY2012. Reasons to Purchase: - Gain understanding of ImmunoGen, Inc and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess ImmunoGen, Inc as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on ImmunoGen, Inc’s business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.